The analysis of MRTs and other SMARCB1-deficient malignant tumours has indicated the consequences of complete SMARCB1 protein loss including profound changes in epigenetic architecture, aberrant activation of transcriptional and metabolic programs that promote cell growth, deregulation of stem cell maintenance and suppression of terminal differentiation [23–26]. The gene discussed is SMARCB1; the disease is neoplasm.